AZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL
This announcement contains inside information 27 July 2017 07:05 BST ASTRAZENECA AND MERCK ESTABLISH STRATEGIC ONCOLOGY COLLABORATION Collaboration aims to maximise the potential of PARP and MEK inhibitors in combination with PD-L1/PD-1 medicines, based on growing scientific evidence that these combinations offer new potential for the treatment of a range of tumour types AstraZeneca and Merck will independently develop and commercialise Lynparza and potential medicine selumetinib in combinations with companies' respective PD-L1/PD-1 immuno-oncology medicines Imfinzi and